|
Synonyms: ATN-103 | PF-5230896
Compound class:
Antibody
Comment: Ozoralizumab is a trivalent albumin-binding nanobody that binds to and neutralises circulating TNFα. This biologic agent is being investigated for anti-inflammatory potential. The peptide sequence for ozoralizumab submitted in its WHO INN record is identical to SEQ ID NO: 96 (TNF30) in patent US8703131 [1], and identifies the albumin nanobody as ALB8. The patent claims a trivalent construct of TNF30-linker-ALB8-linker-TNF30.
|
| References |
|
1. Beirnaert EAA. (2014)
Nanobodies against tumor necrosis factor-alpha. Patent number: US8703131. Assignee: Ablynx N.V.. Priority date: 21/05/2005. Publication date: 22/04/2014. |
|
2. Kratz F, Elsadek B. (2012)
Clinical impact of serum proteins on drug delivery. J Control Release, 161 (2): 429-45. [PMID:22155554] |
